Press releases
- Mahesh Krishnan Elected to Halozyme's Board of Directors
- Halozyme to Report First Quarter 2024 Financial and Operating Results
- Halozyme to Participate in Upcoming Investor Conferences
- HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
- Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
More ▼
Key statistics
On Tuesday, Halozyme Therapeutics Inc (RV7:DUS) closed at 36.06, -11.47% below its 52-week high of 40.73, set on Aug 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.06 |
---|---|
High | 36.06 |
Low | 36.06 |
Bid | 35.61 |
Offer | 35.80 |
Previous close | 35.92 |
Average volume | 0.00 |
---|---|
Shares outstanding | 127.05m |
Free float | 125.68m |
P/E (TTM) | 18.07 |
Market cap | 4.84bn USD |
EPS (TTM) | 2.11 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 07:11 BST.
More ▼